Benefit Absence of Therapeutic Moderate Hypothermia in the Treatment of Cardiac Arrest: A Systematic Review and Meta-Analysis

García García Miguel Ángel1*, Rosero Arenas María de los Ángeles2, Pérez Lluna Leticia3, Martínez Cornejo Alfonso1, Arizo León David1

1ICU Department, Hospital de Sagunto, Valencia, Spain
2Primary Care Center, Cheste, Valencia, Spain
3Internal Medicine Department, Hospital de Sagunto, Valencia, Spain

Email address: mangelesmangel@gmail.com (G. G. M. Ángel)

*Corresponding author

To cite this article:
García García Miguel Ángel, Rosero Arenas María de los Ángeles, Pérez Lluna Leticia, Martínez Cornejo Alfonso, Arizo León David. Benefit Absence of Therapeutic Moderate Hypothermia in the Treatment of Cardiac Arrest: A Systematic Review and Meta-Analysis. Cardiology and Cardiovascular Research. Vol. 2, No. 2, 2018, pp. 29-48. doi: 10.11648/j.ccr.20180202.13

Received: August 10, 2018; Accepted: August 30, 2018; Published: September 25, 2018

Abstract: Background: Hyperthermia is frequent after cardiac arrest, and is associated with poor vital and neurological prognosis. In the last few years there have been published some studies that show benefits with moderate hypothermia in these patients, and other studies haven’t shown such benefits. Aim: To collect all clinical trials evaluating the utility of moderate therapeutic hypothermia in survivors of a cardiac arrest. Method: A comprehensive search of clinical trials evaluating moderate hypothermia in patients who survive a cardiac arrest was carried out. The mortality and quality of life of the survivors were evaluated. The quality of the included studies, the publication bias and the heterogeneity of the results were evaluated. Results: there is no significant reduction in mortality (RR 0.97, 95% CI 0.93-1.01) or increase in quality of life (RR 1.07, 95% CI 0.94-1.21) of the patients undergoing moderate hypothermia versus those not treated with that. There are no different results in patients with cardiac arrest with defibrillable and non – defibrillable rhythms, with the different used cooling methods, or even with the induction of intra – cardiac arrest hypothermia. The mortality of these patients is high, and there are no significant differences in relation to the age or sex of them. Conclusion: In patients who survive a cardiac arrest, the induction of moderate hypothermia is not recommended.

Keywords: Therapeutic Hypothermia, Cardiac Arrest, Mortality, Survival with Good Neurological Prognosis

1. Introduction

Cardiac arrest (CA) is defined as the cessation of heart beat of myocardial contraction [1]. In Europe, there are about 350,000-375,000 sudden CA a year outside the hospital, with estimated numbers of 17 – 53 patients with CA treated by the Emergency Medical Systems / 1000,000 habitants / year [2]; the one year-survival of patients suffering from CA varies between countries, being the average is 10% [3, 4]. Currently it is demonstrated that if a serie of successive actions, which can be performed by most people, called “Cardiopulmonary Resuscitation (CPR) manoeuvres”, included into the “Chain of Survival”, could increase survival in 2-3 times; however, these maneuvers are only carried out in 1 of every 5 people who suffer CA outside the hospital; hence, the importance of education to the general population [5].

In the first 48 hours after CA, a period of hyperthermia is frequent. A relationship between post-CA hyperthermia and poor prognosis has been demonstrated [6]. It is reasonable to treat hyperthermia in unconscious patients who survive a CA. Several studies done in animals and humans show that mild hypothermia is neuroprotective and improves prognosis after
a period of global cerebral ischemia [7]. The promising findings of 2 clinical trials of moderate hypothermia (MH) in survivors of a CA caused by ventricular fibrillation (VF) [8, 9] supported the recommendation of MH in the following CPR Guidelines of the European Resuscitation Council (ERC) [10], and even by analogy in CA situations of non-shockable rhythm. The inconclusive recent results of the Nielsen study [11] reduced the euphoria about the usefulness of this therapy, which became only a careful control of temperature and not of MH [12].

It is not clear if an intervention such as MH in CA is more or less useful depending on several factors: the observed cardiac rhythms in a CA situations; if the beginning of hypothermia at extra or intrahospital level, or even coinciding with cardiopulmonary resuscitations maneuvers; or the applied mechanism of hypothermia.

Hence the reason for this systematic review and meta-analysis: to collect all clinical trials conducted in recent years that evaluate the usefulness of MH to have a global view of its effectiveness, and perform subgroup analyzes to analyze whether this therapy may be more effective in some subgroups of patients.

2. Methods

2.1. Initial Objective

Our objective was to assess the efficacy of inducing MH in reducing mortality and/or increasing the survival of patients with good neurological prognosis. A board search in several databases was carried out, trying to find randomized controlled trials in which MH was compared with the absence of hypothermia. A comprehensive systematic review was carried out according to the recommendations concerning design quality of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement [13].

2.2. Included Population

Patients were adults who have had recovery of spontaneous circulation (ROSC) after CA. There are a lot of causes of CA. The study did not included patients in the context of severe trauma, a severe toxicological or metabolic disturb / drug overdose, severe hypothermia (<= 30°C) or being pregnant women.

2.3. Intervention

The evaluated intervention was the application of MH to survivors of CA. All types of hypothermia were assessed: external - applied on skin and mucous membranes- versus internal -infusion of cold fluid or cooling of blood in extracorporeal circuit-; extrahospital vs intrahospital, even intra-CA; etc.

2.4. Search of Clinical Trials

Several electronic databases were consulted:
   i. Pubmed, with a broad strategy and search syntax:
   ("Cardiopulmonary Resuscitation"[Majr] OR "Heart arrest"[All Fields]) AND "Hypothermia, induced"[Majr]) AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Review[ptyp];
   ii. Clinicaltrials.gov, Trypdatabase, CENTRAL (Cochrane Central Register of Controlled Trials) and OVID, with a similar strategy -(cardiopulmonary resuscitation OR heart arrest) AND (hypothermia induced)-.

These databases were finally revised on May 6th, 2018. All this information was supplemented with bibliographic references in several found systematic reviews and meta-analysis. We searched for the results of completed studies referred in ClinicalTrials.gov.

A priori there was no limits on language or date of publication.

2.5. Obtaining Results

Basic information (population, intervention, outcomes) and methodological quality (risk of bias) were obtained from the finally accepted studies in a peer review process; in aspects where there was no coincidence, an agreement was reached with the help of a third evaluator. Hypothermia was achieved with external and/or internal methods, and with adequate doses of sedation, analgesia and muscle relaxation.

2.5.1. Mathematical Analysis

Efficacy of MH was measured with reduction of global mortality and increased survival of patients with good neurological prognosis. This good neurological prognosis was measured with 2 scales: Pittsburgh Cerebral Performance Category (PCCP) of 1 (good cerebral performance: conscious, alert, able to work, might have a mild neurological or psychological deficit) or 2 (moderate cerebral disability: conscious, sufficient cerebral function for independent activities in daily life, able to work in sheltered environment) [14]; and modified Rankin scale of 0 (no symptoms), 1 (no significant disability) or 2 (slight disability) [15]. These dichotomous variables were evaluated with a relative risk (RR) (probability of patients with the event in the moderate hypothermia group / probability of patients with the event in the control group). There would be a positive effect if the RR of mortality is <1, and if the RR of patients with good neurological prognosis is > 1.

Since the heterogeneity between studies was probable, the random effects model was assumed and calculations were made using the Maentel-Haenszel model.

The quality of included studies was assessed with 2 methods: the 5 items included in the Bias Assessment Tool of the Rev Man programme; generation of randomisation sequence, concealment of randomisation sequence, patient and doctor blinding, blind assessment of outcomes and incomplete follow-up [16]; and Jadad scale, that evaluates randomisation sequence, blinding and incomplete follow-up [17].

The assessment of the publication bias was made with 2 methods: graphs (funnel-plot) and numerical, with the calculation of the number of unpublished studies with the
2.5.2. Employed Software

Calculations were made using the Cochrane Collaboration Review Manager 5.3 program, the J Primo EXCEL spreadsheet posted on the CASPe website (www.redcaspe.org) and with STATA / IC v.14.2.

3. Results

The bibliographic search described above was carried out (figure 1). 38 clinical trials and 19 meta-analyses were obtained. The abstract of a clinical trial of the year 2000 [18] was obtained; it was randomized, but with insufficient methodological data, so it was not included in the meta-analysis.

Finally, 16 clinical trials were evaluated [8, 9, 11, 19, 32]. They are described in the Table of Characteristic of Included Studies (Appendix). The overall quality of the studies is shown in Fig. 2. Blinding of the patients and clinicians in this situation is impossible, so they can not be double blind; as an internal validity finding, in most studies blinding in the evaluation of the functional prognosis of the patient is blind. Randomization is usually well done, with the exception of one of the initial pivotal work [19] that could clearly magnify its beneficial effect. The individual evaluation of each work is shown in Figure A1 (Appendix).
Figure 2. Global evaluation of the quality items of the Risk of Bias toolkit of the Cochrane Collaboration.

Figure 3. Global comparison of mortality of patients with hypothermia vs without hypothermia. A RR < 1 is an estimate in favor of hypothermia.

Figure 4. Funnel plot of included studies in the global evaluation of mortality.
The overall effectiveness of MH in terms of mortality variation is shown in Figure 3. Few studies show a significant reduction in mortality [8, 25]. The overall estimate shows no benefit with this intervention, with a RR of 0.97 and the estimation by confidence interval that exceeds the unit, and estimates of mortality in each branch of 67.7 and 68.9%. The funnel plot (fig 4) of these trials shows that there seems to be no publication bias; Neither the Rosenthal nor the Glesser-Olkin methods yield results that guide the presence of unpublished studies with non-significant results.

Overall results in terms of improvement in neurological prognosis also show no significant differences. Figure 7 shows a minimal non-significant trend towards improvement of the RR (1.07, with 95% CI between 0.94 and 1.21) with 27.5 and 26.6% of patients with good prognosis in each branch. In the funnel plot (fig 8) a striking asymmetry of studies is observed, which may be related to publication bias -not publication of some works without absence of neurological prognosis benefit-. However, as in the previous section on mortality, the Rosenthal and Glesser-Olkin methods provide non-significant results. Figures A2 and A3 (Appendix) show analogous results to that described for the analysis of subgroups against mortality: absence of benefit in both defibrillable and non-defibrillable rhythms, and percentages of patients with good neurological results of 50.4 and 49.3% for the assumption of defibrillable rhythms, and 12.3 and 10.9% in rhythms that cannot be defibrillated.
Figure 7. Global comparison of percentage of patients with good neurological prognosis with hypothermia vs without hypothermia. A RR > 1 is an estimate in favor of hypothermia.

Figure 8. Funnel plot of included studies in the global evaluation of good neurological prognosis.

Assessing mortality, the cumulative meta-analysis of the 16 studies shows a striking curve (fig 9): initial benefit, with an estimate clearly below the unit in the first studies / years, with a trend towards no benefit from the year 2010, which is maintained from 2013.
The type of cooling is an element that can influence the final outcome of the patient. Figure 10 shows the subgroup analysis of the studies according to the type of used cooling method. The internal methods (mostly obtained by infusion of cold saline, at 4°C) and the mixed, combination of internal and external methods, do not provide mortality benefit, while the aggregated estimation of the works with external cooling seems to show certain benefit (RR 0.85, with CI 95% from 0.76 to 0.95); however, this estimate is made on a small group of patients (only 10.87% of the total number of patients included in the meta-analysis). In recent years there is a greater use of intranasal cooling, although mostly in combination with other methods: the only found studies in which this method is used alone are Castren [24] (without significant difference in mortality) and Belohlavek [31] (without significant differences in neurological prognosis). No significant differences were found either in mortality - RR 1.01 (0.97 - 1.04) - nor in neurological prognosis - RR 1.01 (0.75 - 1.35) - in the studies that perform intra-CA cooling [30, 33, 34].
The evaluation of the methodological quality of the studies provides surprising data. We can use the Jadad scale, and describe the low quality studies with a score <3 points, and high quality with ≥ 3 points. Subgroup analysis (Figure 11) shows no benefit in high quality studies (RR = 1) and a trend to statistical significance in studies with lower quality (RR = 0.8). The result is analogous for the assessment of neurological prognosis (figure A4). If the quality is managed as a continuous numerical variable, and a meta-regression is made, the result does not become statistically significant, but a greater slope of a line between a higher quality and an absence of effect (RR next to 1). In other words, at a lower methodological quality of the works, a greater reduction in mortality is observed (Figure A5). There are also no notable differences if the studies are published in Core Clinical Journals (journals of greater impact and quality) than in other journals (figure A6).

**Figure 10. Analysis of subgroups of the different types of cooling used.**

| Author       | Year | RR (95% CI) | % Weight |
|--------------|------|-------------|----------|
| ext          |      |             |          |
| Bernard      | 2002 | 0.76 (0.52, 1.10) | 1.32    |
| Castren      | 2010 | 0.98 (0.87, 1.09) | 4.49    |
| Hachimi      | 2004 | 0.81 (0.57, 1.16) | 1.16    |
| Holzer       | 2002 | 0.74 (0.68, 0.96) | 3.89    |
| Subtotal     |      | 0.85 (0.76, 0.95) | 10.87   |
| int          |      |             |          |
| Bernard RICH | 2010 | 1.13 (0.87, 1.46) | 2.80    |
| Bernard RICH | 2012 | 0.95 (0.85, 1.06) | 3.83    |
| Bernard RINSE| 2016 | 1.01 (0.97, 1.05) | 27.26   |
| Kamarainen   | 2009 | 1.09 (0.68, 1.73) | 0.66    |
| Kim2007      | 2007 | 0.94 (0.74, 1.19) | 2.28    |
| Kim2014      | 2014 | 0.99 (0.91, 1.08) | 21.96   |
| Laurent      | 2005 | 1.24 (0.76, 2.02) | 0.59    |
| Pang         | 2016 | 0.80 (0.47, 1.35) | 0.44    |
| Subtotal     |      | 1.01 (0.97, 1.05) | 59.82   |
| both         |      |             |          |
| Debaty       | 2014 | 0.98 (0.93, 1.04) | 6.04    |
| Nielsen      | 2013 | 1.01 (0.88, 1.16) | 11.39   |
| Petrovic     | 2011 | 0.55 (0.38, 0.79) | 1.69    |
| Scales       | 2017 | 0.99 (0.88, 1.10) | 10.20   |
| Subtotal     |      | 0.97 (0.91, 1.04) | 29.32   |
| Overall      |      | 0.98 (0.95, 1.01) | 100.00  |
The influence that the sex or age of the patients can have is evaluated in figures A7 and A8 of the Appendix. Meta-regression (in which are assessed the average / median age of the patients included in each study, their effect and sample size, in relation to the RR of mortality) does not yield statistically significant data. A higher percentage of men and older populations are related with a greater mortality (RR > 1), with a slope of the line slightly higher for a higher age than for a higher percentage of men, although in both cases this slope seems minimally positive.

Finally, the assessment of the degree of efficiency of the technique as a function of the mortality rate in each study is assessed with the L'Abbé chart (Figure A9 Appendix). We can see most of the effect estimates on the bisector of the graph, which means that the RR of death is 1; in some studies with a risk of death of 0.4-0.7 the RR seems to be < 1 (there are several circles plotted below that bisector); but the number and area of trials with RR of 1 is much higher, so the overall effect must be close to unity.

4. Discussion

The result of our work is conclusive. There is no benefit in survival or favorable neurological prognosis of the application of MH measures. And this finding is independent of the heart rhythm present at the CA, the cooling method used, the age or sex of the patients treated, or the mortality rate of the patients included in the studies. It should be noted that heterogeneity in terms of the methods used for cooling, the temperature sought and achieved with cooling, and the time of hypothermia (see Table of Characteristic of Included Studies, Appendix); these factors can contribute to an absence of significant results. Perhaps, one specific mode of moderate hypothermia can achieve benefits, but with this study we can’t probe this assumption and it seems very unlikely. In recent years, the tendency is starting hypothermia at the beginning of CA. The current global result is the lack of benefit of this intervention. Without being conclusive, it is striking that the degree of benefit shown by the intervention is inversely proportional to
the quality of the study.

The cumulative meta-analysis curve is surprising. In other published cumulative meta-analyses that evaluate effective therapeutic interventions [33, 34], the initial estimates are close to the absence of effect, and with the accumulation of data from successive studies the effect is outlined as significant (RR or OR apart from 1). In our graph it seems to be the opposite, with initial significant effect and final estimation without effect (RR or OR = 1). The revision of the cardiopulmonary resuscitations recommendations is carried out every 5 years, the last one in 2015. Perhaps the change in the words and in the intention of the hypothermia in the CA (we remember, not as MH, but as "careful handling of the temperature ", more in the sense of avoiding hyperthermia) could have been ahead of time.

Up to now, 19 meta-analyses have been published with the aim of evaluating MH in CA (citations A to S in Appendix). Of them, 10 (#A - J) are favorable to the application of this therapy, most of them prior to 2013, although the most representative one, which is the last revision of this topic by the Cochrane Collaboration, has been made in 2016. 3 of these works (#C, D and E) give favorable results, but cast doubts (limited data, low level of evidence). The remaining 9 (#K - S), with unfavorable result to MH, are all dated 2013 or later. The results of our work are concordant with these last meta-analyses. As it has happened a lot of times in the history of Medicine, an intervention recommended at one time was not recommended a few years later. It gives the impression that the moment of MH in CA has passed.

The most recent studies, aimed at the use of intranasal cooling devices, or with the initiation of intra-CA cooling, also show no reduction in mortality or improvement in neurological prognosis. Soon the results of several works developed in recent years will be published [35, 36]; with the absence of previously demonstrated benefit, it is unlikely that these data reverse the trend of no benefit. Perhaps the future of MH in the management of CA survivors is that reflected in the latest CPR Guidelines (2015) [11] as "temperature control" only in the sense of avoiding hyperthermia.

5. Conclusion

In patients who survive a CA, the induction of MH doesn’t get improvement in survival or neurological prognosis, therefore it isn’t recommended in these patients.

Acknowledgements

Our thanks to Isabel María Álvarez, Technical Assistant of Scientific Information of GSK (Glaxo Smith Kline) company, by her help in getting several articles; to Lucía García, a future doctor who will be a better physician than her parents; to Alberto García, for his help with the editing of the images; and, in general, to all the staff of the Intensive Care Unit of the Hospital de Sagunto, for their encouragement to carry out this work.

Contributors

All authors have contributed to the development of the work. MAGG and MARA have made the bibliographic search and collected the studies to be reviewed; MAGG, AMC, LPLL, MARA and DAL have reviewed the finally included studies in the revision; MAGG y LPLL have performed the mathematical analysis; and MAGG, AMC and MARA have drawn the final conclusions and translated the manuscript into English.

Competing Interest

The authors declare no conflict of interests.

Funding

There is no source of funding of this study.

Bioethics Note

This study is a systematic review and meta-analysis of clinical trials. According to the declaration of Helsinki, it is not necessary for its development to be approved by the Bioethics Committee of the Hospital de Sagunto.

Note

All web links have been visited for the last time on August 20, 2018.

Key Messages

What is already known about this subject?
1. Hyperthermia in survivors of PC seems to worsen the prognosis.
2. It is advisable the careful handling of the temperature of the patients that survive a PC

What does this study add?
1. Moderate hypothermia does not seem to provide a benefit in reducing mortality or improving neurological prognosis.
2. There is no benefit in any cardiac arrest situation: rhythms defibrillable or not, different hypothermia devices, etc

How might this impact on clinical practice?
1. The induction of moderate hypothermia in survivors of CA should not be mandatory.
2. It seems advisable to avoid post-cardiac arrest hyperthermia.
## Appendix

### Appendix A. Table of Characteristics of Included Studies

| Authors | Year | Interventions | Outcomes | Others |
|---------|------|---------------|----------|--------|
| Bernard 2002 NEJM | May 1999 – June 1999 | Patients with initial cardiac rhythm of ventricular fibrillation (VF), persistent coma after the return of spontaneous circulation (ROSC). PREHOSPITAL HYPOTHERMIA (HT). Paramedics began measures in the field to initiate HT by removing clothing and applying EXTERNAL cold packs to the patient’s head and torso with a temperature target of 33°C; this temperature was maintained until 12 hours; beginning at 18 hours, patients were actively rewarmed for the next 6 hours. The treatment of patients assigned to normothermia (NT) followed usual prehospital treatment protocols. 12 hours after admission: 32.7°C (HT) vs 37.1°C (NT). 18 after admission, 36 vs 37.4°C. This study was supported by grants from the Biomedicine and Health Programme (BIOMED2) of the European Union, the Ministry of Science and the Austrian Science Foundation. | Discharge from the hospital. Discharge to home, or to a rehabilitation facility (good outcome), or also to a long-term nursing facility (poor outcome). There’s no clear information about funding. | |
| Holzer 2002 NEJM | March 1996 – January 2001 | Europe (Austria, Italy, Belgium, Finland). Witnessed cardiac arrest (CA), VF or non-perfusing ventricular tachycardia (VT) as the initial cardiac rhythm, a presumed origin of CA, age of 18 – 75 years, interval of 5-15 minutes from collapse to 1st attempt at resuscitation by emergency medical personnel. PREHOSPITAL HT. Patients in the HT group were cooled to a target temperature of 32-34°C with an EXTERNAL cooling device (matress that delivers cold air over the entire body). Goal was to reach this target within 4 hours after ROSC, and was maintained for 24 hours, followed by passive re-warming. Patients assigned to NT group were placed on conventional hospital beds and NT was maintained. | 1st outcome: Favorable neurological outcome within 6 months, defined as Cerebral Performance Category (CPC) of 1 (good recovery) or 2 (moderate disability). 2nd outcomes: mortality at 6 months, rate of complications during first 7 days after CA. | Peripheral blood simple of S-100B. Neurological outcome from the first week up to 6 months. There’s no clear information about funding. | |
| Hachimi-Idrissi 2004 Resuscitation | October 1999 – June 2002 | Europe (Belgium). Adults with CA and cardiopulmonary resuscitation (CPR) after non-traumatic CA with ROSC who were admitted to Department of Emergency. PREHOSPITAL and INTRAHOSPITAL HT. Patients with asystole or pulseless electrical activity assigned to HT a helmet device to induce mild HT (33°C) was placed on the head of the patients at the scene. When a body temperature of 33°C was reached, within 4 hours, helmet was removed and patients were allowed to regain NT passively and slowly during the next 18 hours. Patients with VF or non-perfusing VT were cooled as soon as they were admitted to Emergency room with a cooling device (matress that delivers cool air), and aiming to reach a body temperature of 33°C, maintaining this for 24 hours. Patients randomised to NT were allowed to re-warm up passively to NT and kept at NT. | Survival with a follow-up time of 6 months. Survival with a favorable neurological outcome (CPC 1-2). | There’s no clear information about funding. | |
| Laurent 2005 JACC | May 2000 – March 2002 | Europe (France). Patients consecutively admitted to Intensive Care Unit (ICU) who were admitted to Department of Emergency. INTRAHOSPITAL HT. 3 strategies: isovolumic high-volume hemofiltration (HF) (200 ml/kg/hour over 8 hours) with a temperature of the fluid at 37°C; HF + HT, with a temperature of the fluid set at 30°C, INTERNAL COOLING, and was decreased to 15°C with ice packs around the infusion line; at the end of HF, mild HT (32-33°C) was maintained by EXTERNAL cooling for 16 hours. And control group with standard supportive care. We compared data from HF vs HF+HT groups. | | |
| Kins 2007 Circulation | February 2006 | USA. November 2004 – February 2006. Patients admitted to acute care hospitals and resuscitated by paramedics after out-of-hospital CA. PREHOSPITAL HT. Infusion of 500-2000 ml of 4°C normal saline without adjusted to body weight (INTERNAL COOLING) before hospital arrival, vs standard care. Mean temperature decrease -1.24 °C, hospital arrival 34.7°C vs -0.1°C, hospital arrival 35.7°C. There was much variability in the subsequent management of temperature, with HT and NT. | Esophageal temperature. Deaths before hospital admission. In-hospital deaths. Discharged alive. Discharged with severe neurological deficits. Safety data from first 12 hours. | Supported by a grant from the Medice Ine Foundation and National Institutes of Health. | |
| Kamarainen 2009 Acta Anaesthesiol Scand | May 2005 – December 2008 | Finland. Patients >= 18 years, regardless of the initial cardiac rhythm. PREHOSPITAL HT. Rapid infusion of 4°C Ringer’s acetate at a rate of 100 ml/min (INTERNAL COOLING). The target naso-pharyngeal temperature was set at 33°C. In the conventional group, | | There’s no clear information about funding. | |

### Table A1. Characteristics of included studies.
| Patients | Interventions | Outcomes | Others |
|----------|---------------|----------|--------|
| Bernard RICH 2010 Circulation | rhythm, with ROSC > 9 minutes and consciousness remained lowered. | PREHOSPITAL HT. Infusion by paramedics of up to 2000 ml of ice-cold lactated Ringer’s solution during transport to hospital (INTERNAL COOLING); standard measures in control group. Posterior intra-hospital maintenance of HT at a target temperature of 33ºC for 24 hours. |characteristic, resuscitation details and outcome data to discharge. | Grants from the Australian National Health and Medical Research Council, and the National Heart Foundation of Australia. |
| Castren 2010 Circulation | patients with a treatment interval (delay of the start of CPR maniouvres) <= 20 minutes. | INTERNAL + EXTERNAL COOLING (cooling pads) during 24 hours, in the first 240 minutes after ROSC, after which spontaneous rewarming started. EXTRAHOSPITAL COOLING. Posterior cooling according to ILCOR protocol, with lowering temperature to 32-34ºC over a 12-24 hours period, when the initial rhythm is VF. | Neurological outcome (CPC), and mortality rate after 30 days | This work was supported by BeneChill, Inc, San Diego, USA. |
| Petrovic 2011 Vojnosanit Pregl | Consecutive comatose patients admitted to a clinic after CA an ROSC. | PREHOSPITAL HT. Infusion by paramedics of up to 2000 ml of ice-cold lactated Ringer’s solution during transport to hospital (INTERNAL COOLING); standard measures in control group. Posterior intra-hospital maintenance of HT at a target temperature of 33ºC for 24 hours. | Proportion of patients with a favorable outcome at discharge. Temperaturas at hospital arrival, prehospital pulmonary edema, and recurrent prehospital CA. | Grants from the Australian National Health and Medical Research Council, and the National Heart Foundation of Australia. |
| Bernard RICH 2012 Crit Care Med | Out-of-hospital CA with an initial rhythm of asystole or pulseless electrical activity. CA time > 10 minutes. | Target management temperature (TTM) at 33 vs 36ºC. EXTRAHOSPITAL INTERNAL + EXTERNAL COOLING. Achieve the assigned temperature as rapidly as possible with ice-cold fluids, ice-packs; intravascular or surface temperature management devices at the discretion of the sites. After 28 hours, gradual rewarming. | All adverse events through 24 hours to day 7. Time in the ICU. Cooling rates, ROSC rate, survival to discharge, survival with good neurological outcome at hospital discharge. | There’s no clear information about funding. |
| Belohlavek 2012 J Translational Med (abstract Resuscitation 2016) | Europe (Czech Republic). Witnessed refractory out-of-hospital CA of cardiac origin. | PREHOSPITAL INTRA-ARREST HT. Hiperinvasive arm with mechanical compression device (LUCAS) with intranasal evaporative cooling Benechill (EXTERNAL COOLING) vs standard arm. Mild HT (33-34ºC) will be started as soon as possible after ROSC. | 6 months survival with good neurological prognosis (CPC 1-2) | Economical support by Puroklima, a companyu distributor for Benechill. |
| Nielsen 2013 NEJM | Out-of-hospital CA of presumed cardiac cause, unconscious survivors. > 20 minutes of ROSC. | EXTRAHOSPITAL INTRA-ARREST COOLING. Infusion of up to 2000 ml of ice-cold 0.9% saline solution at 100 ml/min during CA. Also surface cooling was also induced using gel pads (INTERNAL + EXTERNAL COOLING) vs control group. | All-cause mortality through the end of the trial. Neurological function (CPC and modified Rankin scale) and death after 180 days. | Supported by independent grant for the Swedish Heart-Lung Foundation. |
| Debaty 2014 Intensive Care Med | France (Europe). | Serum concentration of neuron-specific enolase (NSE) at baseline, 3, 6, 12, 24, 48 and 72 hours. Neurological outcome at hospital discharge and 30 days, using the Pittsburgh CPC categories. | Grant from the French Society of Emergency Medicine. |
| Kim 2014 JAMA | USA. DECEMBER 2007 – DECEMBER 2012. Adults with pre-hospital CA, with VF and non-VF rhythms. | Survival and neurological status at discharge. | This study was funded by grants from the National Heart, Lung and Blood Institute. | |
| Patients | Interventions | Outcomes | Others |
|----------|---------------|----------|--------|
| Pang 2016 J Cardiothoracic Surg | INTRAHOSPITAL and INTRAVASCULAR COOLING. Cooling to a target temperature of 34°C by modulating the heat exchanger component of the ECLS circuit, and maintained at 34°C for 24 hours in the ICU. | Neurological status (CPC 1-2) and survival to hospital discharge and 6 months. | This study was supported by a SingHealth Foundation Grant. |
| Bernard RINSE 2016 Circulation | EXTRAHOSPITAL AND INTRAVASCULAR COOLING. Rapid intravascular infusion of up to 21/30 ml/kg of cold saline DURING CARDIOPULMONARY RESUSCITATION vs standard care. After arrival at the emergency department, all patients receive standard care that may include cooling to 33°C for 24 hours. | Survival at hospital discharge. % ROSC of patients with shockable / non-shockable rhythms. | This study was funded by the National Health and Medical Research Council. Was closed early due to changes in temperature management at major receiving hospitals. |
| Scales 2017 Resuscitation | EXTRAHOSPITAL COOLING, INTERNAL + EXTERNAL COOLING (surface ice packs, cold saline infusion) initiated 5 minutes after ROSC, vs no-prehospital cooling. All in-hospital procedures, including application of TTM, were left at the discretion of the treating clinical team. | Achieving a target temperature of 32-34°C within 6 hours of emergency department arrival. Survival with good neurological outcome (CPC 1-2) at hospital discharge. | This study was funded by a grant from the Canadian Institute of Health Research. |

**Appendix B. Additional Figures**

![Figure A1. Quality description of each study included in the meta-analysis.](image-url)
Figure A2. Comparison of percentages of patients with good neurological prognosis mortality in shockable rhythms. A RR > 1 is an estimate in favor of hypothermia.

| Study or Subgroup | Experimental Events Total | Control Events Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|----------------------|--------|-----------------------------|
| Bernard 2002      | 21 43 39 34             | 18 36 32 30         | 1.8%   | 1.84 [0.87, 3.96]           |
| Bernard PRINCE 2010 | 80 118 61 110          | 70 108 63 102       | 5.9%   | 1.55 [0.95, 2.52]           |
| Hachmeister 2004  | 8 14 8 14              | 8 14 8 14           | 0.5%   | 1.31 [1.06, 1.55]           |
| Holzer HAOA 2002  | 75 136 56 127          | 60 112 48 105       | 1.5%   | 0.67 [0.51, 0.90]           |
| Kereiines 2009    | 8 23 8 20              | 8 23 8 20           | 1.6%   | 1.83 [1.06, 3.13]           |
| Kim 2007          | 17 29 8 22             | 17 29 8 22          | 1.4%   | 1.03 [0.60, 1.78]           |
| Kim 2014          | 166 292 180 291        | 146 230 160 259     | 32.4%  | 0.91 [0.41, 1.21]           |
| Nielsen TT 2013   | 218 473 222 466        | 218 473 222 466     | 40.1%  | 0.97 [0.84, 1.11]           |
| Total (95% CI)    | 1144 2576 1121 1000    | 1144 2576 1121 1000 | 100%   | 1.02 [0.94, 1.11]           |

Total events: 2576

Heterogeneity: Ch² = 16.23, df = 8 (P = 0.04), I² = 51%

Test for overall effect: Z = 0.56 (P = 0.57)

Figure A3. Comparison of percentages of patients with good neurological prognosis mortality in non-shockable rhythms. A RR > 1 is an estimate in favor of hypothermia.

| Study or Subgroup | Experimental Events Total | Control Events Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|----------------------|--------|-----------------------------|
| Bernard 2002      | 21 43 39 34             | 18 36 32 30         | 1.8%   | 1.84 [0.87, 3.96]           |
| Bernard PRINCE 2010 | 80 118 61 110          | 70 108 63 102       | 5.9%   | 1.55 [0.95, 2.52]           |
| Hachmeister 2004  | 8 14 8 14              | 8 14 8 14           | 0.5%   | 1.31 [1.06, 1.55]           |
| Holzer HAOA 2002  | 75 136 56 127          | 60 112 48 105       | 1.5%   | 0.67 [0.51, 0.90]           |
| Kereiines 2009    | 8 23 8 20              | 8 23 8 20           | 1.6%   | 1.83 [1.06, 3.13]           |
| Kim 2007          | 17 29 8 22             | 17 29 8 22          | 1.4%   | 1.03 [0.60, 1.78]           |
| Kim 2014          | 166 292 180 291        | 146 230 160 259     | 32.4%  | 0.91 [0.41, 1.21]           |
| Nielsen TT 2013   | 218 473 222 466        | 218 473 222 466     | 40.1%  | 0.97 [0.84, 1.11]           |
| Total (95% CI)    | 667 1399 661 1000      | 667 1399 661 1000   | 100%   | 1.13 [0.84, 1.52]           |

Total events: 1399

Heterogeneity: Ch² = 4.64, df = 5 (P = 0.46), I² = 5%

Test for overall effect: Z = 0.79 (P = 0.43)

Figure A4. Analysis of subgroups of good neurological prognosis with the methodological quality with Jadad scale. Low indicates Jadad < 3. High indicates Jadad >=3.
Figure A5. Metaregression that assesses the risk of mortality according to the quality measured by the Jadad scale.

Figure A6. Analysis of mortality with the publication in a Core Clinical Journal.
Figure A7. Metaregression that assesses the risk of mortality according to the percentage of men in the study.

Figure A8. Metaregression that assesses the risk of mortality according to the mean/median age of participants in the study.
Figure A9. L’Abbé graph. Graphic comparison of mortality risk in each treatment arm of each study included in the meta-analysis. The absence of benefit of hypothermia is present in studies with lower and higher mortality risk.

Appendix C. Reference List Meta-Analysis

A. Holzer M, Bernard SA, Hachimi-Idrissi S et al. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. Crit Care Med. 2005 Feb;33(2):414-8.
B. Cheung KW, Green RS, Magee KD. Systematic review of randomized controlled trials of therapeutic hypothermia as a neuroprotectant in post cardiac arrest patients. CJEM. 2006 Sep;8(5):329-37.
C. Nielsen N, Friberg H, Gluud C et al. Hypothermia after cardiac arrest should be further evaluated—a systematic review of randomised trials with meta-analysis and trial sequential analysis. Int J Cardiol. 2011 Sep 15;151(3):333-41.
D. Walters JH, Morley PT, Nolan JP et al. The role of hypothermia in post-cardiac arrest patients with return of spontaneous circulation: a systematic review. Resuscitation. 2011 May;82(5):508-16.
E. Scolletta S, Taccone FS, Nordberg P et al. Intra-arrest hypothermia during cardiac arrest: a systematic review. Crit Care. 2012 Dec 12;16(2):R41.
F. Kim YM, Yim HW, Jeong SH et al. Does therapeutic hypothermia benefit adult cardiac arrest patients presenting with non-shockable initial rhythms?: A systematic review and meta-analysis of randomized and non-randomized studies. Resuscitation. 2012 Feb;83(2):188-96.
G. Xiao G, Guo Q, Shu M et al. Safety profile and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta-analysis. Emerg Med J. 2013 Feb;30(2):91-100.
H. Gao Y, Hui KL, Wang YJ et al. Efficacy of mild hypothermia for the treatment of patients with cardiac arrest. Chin Med J (Engl). 2015 Jun 5;128(11):1536-42.
I. Schenone AL, Cohen A, Patarroyo G et al. Therapeutic hypothermia after cardiac arrest: A systematic review/meta-analysis exploring the impact of expanded criteria and targeted temperature. Resuscitation. 2016 Nov;108:102-110.
J. Arrich J, Holzer M, Havel C et al. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database Syst Rev. 2016 Feb 15;2:CD004128
K. Diao M, Huang F, Guan J et al. Prehospital therapeutic hypothermia after cardiac arrest: a systematic review and meta-analysis of randomized controlled trials. Resuscitation. 2013 Aug;84(8):1021-8.
L. Huang FY, Huang BT, Wang PJ et al. The efficacy and safety of prehospital therapeutic hypothermia in patients with out-of-hospital cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2015 Nov;96:170-9.
M. Yu T, Longhini F, Wu R et al. The role of the induction of mild hypothermia in adult patient outcomes after cardiac arrest: Systematic review and meta-analysis of randomized controlled studies. J Int Med Res. 2015 Aug;43(4):471-82.
N. Zhang XW, Xie JF, Chen JX et al. The effect of mild induced hypothermia on outcomes of patients after cardiac arrest: a systematic review and meta-analysis of
randomised controlled trials. Crit Care. 2015 Dec 1;19:417.

O. Villablanca PA, Makkiya M, Eisenberg E et al. Mild therapeutic hypothermia in patients resuscitated from out-of-hospital cardiac arrest: A meta-analysis of randomized controlled trials. Ann Card Anaesth 2016; 19: 4-14.

P. Patel JK, Parikh PB. Association between therapeutic hypothermia and long-term quality of life in survivors of cardiac arrest: A systematic review. Resuscitation. 2016 Jun;103:54-59.

Q. Bhattacharjee S, Baidya DK, Maitra S. Therapeutic hypothermia after cardiac arrest is not associated with favorable neurological outcome: a meta-analysis. J Clin Anesth. 2016 Sep;33:225-32.

R. Nie C, Dong J, Zhang P et al. Prehospital therapeutic hypothermia after out-of-hospital cardiac arrest: a systematic review and meta-analysis. Am J Emerg Med 2016; 34: 2209 – 16.

S. Lindsay PJ, Buell D, Scales DC. The efficacy and safety of pre-hospital cooling after out-of-hospital cardiac arrest: a systematic review and meta-analysis. Crit Care. 2018 Mar 13;22(1):66.

Appendix D. Clinical Trials Excluded from the Meta-Analysis (Flow-Chart)

I. Zeiner A, Sunder-Plassmann G, Sterz F et al. The effect of mild therapeutic hypothermia on renal function after cardiopulmonary resuscitation in men. Resuscitation. 2004 Mar;60(3):253-61.

II. Tiainen M, Parikka HJ, Mäkijärvi MA et al. Arrhythmias and heart rate variability during and after therapeutic hypothermia for cardiac arrest. Crit Care Med. 2009 Feb;37(2):403-9.

III. Tiainen M, Kovala TT, Takkunen OS et al. Somatosensory and brainstem auditory evoked potentials in cardiac arrest patients treated with hypothermia. Crit Care Med. 2005 Aug;33(8):1736-40.

IV. Tiainen M, Poutiainen E, Kovala T et al. Cognitive and neurophysiological outcome of cardiac arrest survivors treated with therapeutic hypothermia. Stroke. 2007 Aug;38(8):2303-8.

V. Tiainen M, Roine RO, Pettilä V et al. Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. Stroke. 2003 Dec;34(12):2881-6.

VI. Jacob M, Hassager C, Bro-Jeppesen J et al. The effect of targeted temperature management on coagulation parameters and bleeding events after out-of-hospital cardiac arrest of presumed cardiac cause. Resuscitation. 2015 Nov;96:260-7.

VII. Lilja G, Nielsen N, Friberg H et al. Cognitive function in survivors of out-of-hospital cardiac arrest after target temperature management at 33°C versus 36°C. Circulation. 2015 Apr 14;131(15):1340-9.

VIII. Lilja G, Nielsen N, Friberg H et al. Cognitive function after cardiac arrest and temperature management; rationale and description of a sub-study in the Target Temperature Management trial. BMC Cardiovasc Disord. 2013 Oct 12;13:85. doi: 10.1186/1471-2261-13-85.

IX. Bro-Jeppesen J, Hassager C, Wanscher M et al. Targeted temperature management at 33°C versus 36°C and impact on systemic vascular resistance and myocardial function after out-of-hospital cardiac arrest: a sub-study of the Target Temperature Management Trial. Circ Cardiovasc Interv. 2014 Oct;7(5):663-72.

X. Maynard C, Longstreth WT, Nichol G et al. Effect of prehospital induction of mild hypothermia on 3-month neurological status and 1-year survival among adults with cardiac arrest: long-term follow-up of a randomized, clinical trial. J Am Heart Assoc 2015; 4: e001693.

XI. Frydland M, Kjaergaard J, Erlinge D et al. Target temperature management of 33°C and 36°C in patients with out-of-hospital cardiac arrest with initial non-shockable rhythm – A TTM sub-study. Resuscitation 2015; 89: 142 –8.

XII. Heard KJ, Peberdy MA, Sayre MR et al. A randomized controlled trial comparing the Arctic Sun to standard cooling for induction of hypothermia after cardiac arrest. Resuscitation. 2010 Jan;81(1):9-14.

XIII. Hongfei L, Ying L, Wanmin H et al. Efficacy and safety of early rapid infusion of icy normal saline in patients after cardiopulmonary resuscitation. Chin Crit Care Med 2014; 26: 710 – 13.

XIV. Look X, Li H, Ng M et al. Randomized controlled trial of internal and external targeted temperature management methods in post- cardiac arrest patients. Am J Emerg Med. 2018 Jan;36(1):66-72.

XV. Grejs AM, Nielsen BRR, Juhl-Olsen P et al. Effect of prolonged targeted temperature management on left ventricular myocardial function after out-of-hospital cardiac arrest – a randomised, controlled trial. Resuscitation 2007; 115: 23 – 31.

XVI. Kirkegaard H, Soreide E, De Haas I et al. Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest. JAMA 2017; 318: 341 – 50.

XVII. Lopez-de-Sa E, Rey JR, Armada E et al. Hypothermia in comatose survivors from out-of-hospital cardiac arrest: pilot trial comparing 2 levels of target temperature. Circulation. 2012 Dec 11;126(24):2826-33.

XVIII. Kim F, Olsufka M, Carlbom D et al. Pilot study of rapid infusion of 2 L of 4 degrees C normal saline for induction of mild hypothermia in hospitalized, comatose survivors of out-of-hospital cardiac arrest. Circulation. 2005 Aug 2;112(5):715-9.

XIX. Hachimi-Idrissi S, Corne L, Ebinger G et al. Mild
hypothermia induced by a helmet device: a clinical feasibility study. Resuscitation. 2001 Dec;51(3):275-81.

XX. Lascarrou JB, Meziani F, Le Gouge A et al. Therapeutic hypothermia after nonshockable cardiac arrest: the HYPERION multicenter, randomized, controlled, assessor-blinded superiority trial. Scandinavian J of Trauma, Resuscitation and Emergency Medicine 2015; 23: 26.

XXI. Nordberg P, Tuccone FS, Castren M et al. Design of the PRINCESS trial: pre-hospital resuscitation intra-nasal cooling effectiveness survival study (PRINCESS). BMC Emergency Medicine 2013; 13: 21.

XXII. Mori K, Takeyama Y, Itoh Y et al. A multivariate analysis of prognosis factors in survivors of out-of-hospital cardiac arrest with brain hypothermia therapy. Crit Care Med 2000; 28 (Suppl): A168 (ABSTRACT).

References

[1] Cardiac arrest MESH definition. Web: https://www.ncbi.nlm.nih.gov/mesh/?term=cardiac+arrest

[2] De Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI et al. Out-of-hospital cardiac arrest in the 1900's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500 – 5.

[3] Gräsner JT, Bossaert L. Epidemiology and management of cardiac arrest: what registries are revealing. Best Pract Res Clin Anaesthesiol. 2013; 27(3):293-306.

[4] Ocen D, Kahungi S, Ejoku J et al. Prevalence, outcomes and factors associated with adult in hospital cardiac arrests in a low-income country tertiary hospital: a prospective observational study. BMC Emergency Medicine (2015) 15:23.

[5] Web: http://www.cercp.org/noticias/noticias-del-cercp/345-recomendaciones-erc-2015 Apartado: Declaración del CERC sobre las nuevas recomendaciones 2015 del European Resuscitation Council (ERC).

[6] Takino M, Okada Y. Hyperthermia following cardiopulmonary resuscitation. Intensive Care Medicine 1991; 17:419-20.

[7] Froehler MT, Geocadin RG. Hypothermia for neuroprotection after cardiac arrest: mechanisms, clinical trials and patient care. J Neurol Sci 2007; 261:118-26.

[8] Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. The New England Journal of Medicine 2002; 346:549-56.

[9] Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. The New England Journal of Medicine 2002; 346:557-63.

[10] Nolan JP, Morley PT, Vanden Hoek TL et al. Therapeutic hypothermia after cardiac arrest. An advisory statement by the Advancement Life support Task Force of the International Liaison committee on Resuscitation. Resuscitation 2003; 57:231-5.

[11] Nielsen N, Wetterslev J, Cronberg T et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. The New England Journal of Medicine 2013; 369: 2197 – 2206.

[12] Monsieurs KG, Nolan JP, Bossaert LL et al. European Resuscitation Council Guidelines for Resuscitation 2015. Section A. Executive summary. Resuscitation 2015; 95: 1-80.

[13] Urrutia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metanálisis. Med Clin 2010; 135: 507-11.

[14] Ajam K, Gold LS, Beck SS et al. Reliability of the Cerebral Performance Category to classify neurological status among survivors of ventricular fibrillation arrest: a cohort study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2011; 19: 38.

[15] Bonita R, Beaglehole R. Modification of Rankin Scale: Recovery of motor function after stroke. Stroke 1988;19:1497-1500.

[16] Assessing risk of bias in included studies. Cochrane methods bias. Web: http://methods.cochrane.org/bias/assessing-risk-bias-included-studies

[17] Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.

[18] Mori K, Takeyama Y, Itoh Y et al. A multivariate analysis of prognosis factors in survivors of out-of-hospital cardiac arrest with brain hypothermia therapy. Crit Care Med 2000; 28 (Suppl): A168 (ABSTRACT)

[19] Hachimi-Idrissi S, Zizi M, Nguyen DN et al. The evolution of serum astroglial S-100 beta protein in patients with cardiac arrest treated with mild hypothermia. Resuscitation. 2005 Feb;64(2):187-92.

[20] Laurent I, Adrie C, Vinsonneau C et al. High-volume hemofiltration after out-of-hospital cardiac arrest: a randomized study. J Am Coll Cardiol. 2005 Aug 2;46(3):432-7.

[21] Kim F, Olsufka M, Longstreth WT Jr et al. Pilot randomized clinical trial of prehospital induction of mild hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4 degrees C normal saline. Circulation. 2007 Jun 19; 115(24):3064-70.

[22] Kamäräinen A, Virkkunen I, Tenhunen J et al. Prehospital therapeutic hypothermia for comatose survivors of cardiac arrest: a randomized controlled trial. Acta Anaesthesiol Scand. 2009 Aug; 53(7):900-7.

[23] Bernard SA, Smith K, Cameron P et al. Rapid Infusion of Cold Hartmanns (RICH) Investigators. Induction of therapeutic hypothermia by paramedics after resuscitation from out-of-hospital ventricular fibrillation cardiac arrest: a randomized controlled trial. Circulation. 2010 Aug 17; 122(7):737-42.

[24] Castren M, Nordberg P, Svensson L et al. Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness). Circulation. 2010 Aug 17; 122(7):729-36.
[25] Petrovic M, Panic G, Jovelic A et al. Therapeutic hypothermia and neurological outcome after cardiac arrest. Vojnosanitetski Pregled 2011; 68: 495 – 99.

[26] Bernard SA, Smith K, Cameron P et al. Rapid Infusion of Cold Hartmanns Investigators. Induction of prehospital therapeutic hypothermia after resuscitation from nonventricular fibrillation cardiac arrest*. Crit Care Med. 2012 Mar; 40(3):747-53.

[27] Debaty G, Maignan M, Savary D et al. Impact of intra-arrest therapeutic hypothermia in outcomes of prehospital cardiac arrest: a randomized controlled trial. Intensive Care Med. 2014 Dec; 40(12):1832-42.

[28] Kim F, Nichol G, Maynard C et al. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: a randomized clinical trial. JAMA. 2014 Jan 1; 311(1):45-52.

[29] Pang PY, Wee GH, Hoo AE et al. Therapeutic hypothermia in adult patients receiving extracorporeal life support: early results of a randomized controlled study. J Cardiothorac Surg. 2016 Apr 5; 11:43.

[30] Bernard SA, Smith K, Finn J et al. Induction of therapeutic hypothermia during out-of-hospital cardiac arrest using a rapid infusion of cold saline. The RINSE trial (Rapid Infusion of Cold Normal Saline). Circulation 2016; 134: 797 – 805.

[31] Belohlavek J, Smid O, Franek O et al. Hyperinvasive approach prolongs the time window for favorable outcomes in refractory out-of-hospital cardiac arrest: A preliminary analysis of the “Prague OHCA Study”. Resuscitation 2016; 1065: e5.

[32] Scales DC, Cheskes çs, Verbeek PR et al. Prehospital cooling to improve successful targeted temperature management after cardiac arrest: a randomized controlled trial. Resuscitation 2017; 121: 187 – 94.

[33] Lau J, Animan E, Jiménez-Silva K et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248 – 54.

[34] García García MA, Rosero Arenas MA, Ruiz Granell R et al. Cardiac resynchronization effectiveness in the treatment of symptomatic heart failure. Systematic review and meta-analysis. Avances Cardiol 2015; 35 (2): 67 – 75.

[35] Lascarrou JB, Meziani F, Le Gouge A et al. Therapeutic hypothermia after nonshockable cardiac arrest: the HYPERION multicenter, randomized, controlled, assessor-blinded superiority trial. Scandinavian J of Trauma, Resuscitation and Emergency Medicine 2015; 23: 26.

[36] Nordberg P, Taccone FS, Castren M et al. Design of the PRINCESS trial: pre-hospital resuscitation intra-nasal cooling effectiveness survival study (PRINCESS). BMC Emergency Medicine 2013; 15: 21.